Cytokinetics, Inc.
Cytokinetics Appoints New CFO
Summary
Cytokinetics, Incorporated has appointed Sung H. Lee as its new Executive Vice President and Chief Financial Officer, effective May 8, 2024. Mr. Lee will succeed Robert I. Blum, the current President and CEO, who has been serving as the principal financial officer on an interim basis. Mr. Lee, who has extensive experience in the biotechnology sector, will receive an annual base salary of $550,000, a target bonus of 45% of his base salary, a signing bonus of $80,000, and substantial equity awards. The appointment is subject to the execution of an employment offer letter and the completion of standard indemnification agreements.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement